Mesenchymal Stem Cell (MSC) Therapy

•Pre-clinical— Strong mechanism, mixed clinical evidence; heavy marketing

What MSCs do (and don’t)

MSCs are multipotent stromal cells that can differentiate into bone, cartilage, fat. The historical "stem cell" framing oversold this: post-infusion, most cells are cleared within days — they rarely engraft. The therapeutic effect, when present, is mostly paracrine: secretion of growth factors, cytokines, and exosomes that modulate the host immune response and tissue repair.

Where the evidence is decent

• Graft-versus-host disease (steroid-refractory): MSC infusion produces remissions; approved as remestemcel-L in Japan, EU.
• Knee osteoarthritis: intra-articular MSC reduces pain and improves function in moderate-quality RCTs.
• Crohn's perianal fistula: darvadstrocel approved (EU).

Where the evidence is poor (despite heavy marketing)

• Systemic "anti-aging" IV infusion.
• Reversing neurodegeneration.
• Reversing chronic disease.
• Improving athletic performance.

Tourism realities

Mexico, Panama, Bahamas, and other jurisdictions offer "stem cell clinics" outside the FDA framework. Risks:

• Unverified cell source and viability.
• Contamination (bacterial, viral).
• Mismatched HLA / immune reactions.
• No adverse-event reporting system.
• Variable physician training.

The FDA has issued multiple consumer warnings.

Exosome-only products

Some clinics market cell-free exosome infusions. Pre-clinical signal is interesting; clinical evidence and quality control are nascent.

Related entries

Stem cell exhaustion, Plasma exchange, Mexico/Bahamas stem-cell tourism.